Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 3
2022 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M. Shadman M. JAMA. 2023 Mar 21;329(11):918-932. doi: 10.1001/jama.2023.1946. JAMA. 2023. PMID: 36943212 Review.
For these patients, first-line treatment consists of a regimen containing either a covalent Bruton tyrosine kinase (BTK) inhibitor (acalabrutinib, zanubrutinib, or ibrutinib) or a B-cell leukemia/lymphoma 2 (BCL2) inhibitor (venetoclax). ...In p …
For these patients, first-line treatment consists of a regimen containing either a covalent Bruton tyrosine kinase (BTK) in …
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC, Elmes JB, Shibu PA, Larck C, Park SI. Moore DC, et al. Ann Pharmacother. 2020 Apr;54(4):371-379. doi: 10.1177/1060028019884863. Epub 2019 Oct 25. Ann Pharmacother. 2020. PMID: 31648540 Review.
Study Selection and Data Extraction: All relevant published articles, package inserts, and unpublished meeting abstracts on mogamulizumab for the treatment of T-cell lymphomas were reviewed. Data Synthesis: Mogamulizumab is an anti-CC chemokine receptor …
Study Selection and Data Extraction: All relevant published articles, package inserts, and unpublished meeting abstracts on mogamulizumab fo …
Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L, Zou X, Chen Y, Bai X, Liang T. Wen L, et al. Front Immunol. 2020 Aug 21;11:2076. doi: 10.3389/fimmu.2020.02076. eCollection 2020. Front Immunol. 2020. PMID: 32973816 Free PMC article.
CASE PRESENTATION: We present the first case of autoimmune diabetes during Sintilimab treatment in a patient with unresectable HCC, accompanied by a remarkable anti-tumor effect of partial regression. ...After plasma glucose is well controlled using insulin t …
CASE PRESENTATION: We present the first case of autoimmune diabetes during Sintilimab treatment in a patient with unres …
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study.
Abuqayyas L, Cheng LE, Teixeira Dos Santos M, Sullivan BA, Ruiz-Santiago N, Wang H, Zhou Y, Chindalore V, Cohen S, Kivitz AJ, Posch MG, Parnes JR. Abuqayyas L, et al. ACR Open Rheumatol. 2022 Oct;4(10):903-911. doi: 10.1002/acr2.11487. Epub 2022 Jul 27. ACR Open Rheumatol. 2022. PMID: 35899378 Free PMC article.
OBJECTIVE: To assess the safety and biological activity of rozibafusp alfa, a first-in-class bispecific antibody-peptide conjugate targeting inducible costimulator ligand (ICOSL) and B cell activating factor (BAFF), in patients with rheumatoid arthritis (RA). …
OBJECTIVE: To assess the safety and biological activity of rozibafusp alfa, a first-in-class bispecific antibody-peptide conju …
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Niehues T, von Hardenberg S, Velleuer E. Niehues T, et al. Allergol Select. 2024 Oct 2;8:304-323. doi: 10.5414/ALX02520E. eCollection 2024. Allergol Select. 2024. PMID: 39381601 Free PMC article.
They include a positive family history and/or signs of pathological susceptibility to infections, immunodysregulation, or syndromic disease. Results of conventional laboratory and most immunological lab studies are not sufficient to make a definitive diagnosis of PAD. ...
They include a positive family history and/or signs of pathological susceptibility to infections, immunodysregulation, or syndromic disea …
Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S, Maurya VK, Kumar S, Ankita, Kaur A, Saxena SK. Mishra S, et al. Curr Eye Res. 2020 Nov;45(11):1325-1341. doi: 10.1080/02713683.2020.1776331. Epub 2020 Jun 21. Curr Eye Res. 2020. PMID: 32567373 Review.
PURPOSE: TAO is an organ specific autoimmune disease associated with thyroid, and inflammation of the orbit and periorbital tissues, which is different from systemic autoimmune diseases such as SLE. ...Recently, FDA-approved teprotumumab a breakthrough, fi …
PURPOSE: TAO is an organ specific autoimmune disease associated with thyroid, and inflammation of the orbit and periorbital ti …